Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib

<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Jussi Koivunen, Craig H. Mermel, Kreshnik Zejnullahu et al. · Clinical Cancer Research · 2008 · 983 citations · Full text

Medicine, Oncology, Pharmacology +17

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Xu‐Chao Zhang, Shirley Zhang, Xue‐Ning Yang et al. · Molecular Cancer · 2010 · 298 citations · Full text

Medicine, Oncology, Pathology +17

EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations

Marcello Tiseo, Francesco Gelsomino, Daniela Boggiani et al. · Lung Cancer · 2010 · 126 citations

Medicine, Genetics, Oncology +17

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation

Yao-Wen Kuo, Shang‐Gin Wu, Chao‐Chi Ho et al. · Journal of Thoracic Oncology · 2010 · 78 citations · Full text

Medicine, Molecular Biology, Oncology +14